Top Regimens by Diagnostic Group April July 2012
Introduction The Top Regimens by Diagnostic Group report provides an overview of the most frequently administered regimens for major tumour sites. Within the report, there may be some records present where the diagnosis does not match the treatment recorded. This report reflects how data has been submitted to CIU. Oral chemotherapy may be under-represented, particularly for haematological groups such as myeloma.
Report Timeframe This report excludes activity for patients under the age of 16 at the time of starting a regimen. Only activity considered to be In Year is included. The recency of activity is derived from all populated date fields. Activity is considered to be In Year if it occurs on or after 1st April 2012.
Definition of Terms The following terms are used in this report: Number of Patients The number of unique patients with a primary diagnosis recorded that matches the relevant diagnostic group. Unique patients are identified by NHS number and postcode. A patient that receives chemotherapy treatment for multiple diagnoses in different diagnostic groupings and within the reporting period specified will be counted more than once.
Definition of Terms The following terms are used in this report: Number of First Cycles The number of patients with a primary diagnosis matching the relevant diagnostic group that have started a cycle of chemotherapy with a recognised regimen grouping. Patients starting multiple different regimens will be counted once in each regimen group. Total Cycles The aggregate total number of cycles delivered of the specified regimen to all patients with a primary diagnosis matching the relevant diagnostic group. This will include first cycles.
Definition of Terms The following terms are used in this report: All submitting trusts aggregated The total aggregated activity for all NHS hospital trusts that have submitted data at the time the report was produced. Coverage across diagnostic groups will vary as not all of the trusts are submitting data for all diagnostic groups at the time the report was produced.
Number of Patients by Diagnostic Group. Brain/CNS 414 (2%) Head and Neck 405 (2%) Other haematology 284 (1%) Other 1376 (5%) Leukaemia 772 (3%) Myeloma 890 (4%) Breast 6062 (24%) Gynae 1881 (7%) Upper GI 2071 (8%) Urology 2139 (9%) Lower GI 3734 (15%) Lymphoma 2172 (9%) Lung 2845 (11%)
Number of Patients by Diagnostic Group.
Number of Patients by Diagnostic Group. Prim ary Diagnosis Sub Group Num ber of Patients (All subm itting trusts aggregated) Leukaemia ALL 69 AML CLL CML 221 274 181 Lymphoma Hodgkin lymphoma 281 Myeloma NHL aggressive NHL indolent NHL NOS T/NK cell NHL plasma cell dyscrasias 619 692 507 73 890 Other haematology MDS 63 MPD 192
Leukaemia (ALL) ICD10: C91.0, C91.5, C91.8
Leukaemia (AML) ICD10: C92.0, C92.3-C92.6, C92.8, C93, C93.0, C93.7, C93.9, C94.0, C94.2-C94.4, C96.2, C96.4, C96.8
Leukaemia (CLL) ICD10: C91.1
Leukaemia (CML) ICD10: C92.1
Lymphoma (Hodgkin lymphoma) ICD10: C81, C81.0-C81.4, C81.7, C81.9
Lymphoma (NHL aggressive) ICD10: C82.4, C83.1, C83.3, C83.5, C83.7, C84.6, C84.7, C85.2
Lymphoma (NHL indolent) ICD10: C82, C82.0-C82.3, C82.6, C82.7, C82.9, C83.0, C88.0, C88.4, C91.3, C91.4, C91.6, C91.7, C91.9
Lymphoma (NHL NOS) ICD10: C82.5, C83, C83.8, C83.9, C85, C85.1, C85.7, C85.9, C88, C88.2, C88.3, C88.7, C88.9
Lymphoma (T/NK cell NHL) ICD10: C84, C84.0, C84.1, C84.4, C84.5, C84.8, C84.9, C86, C86.0-C86.6
Myeloma (plasma cell dyscrasias) ICD10: C90, C90.0-C90.3, D47.2, E85
Other haematology (MDS) ICD10: C92.2, C93.1, C93.3, C94.6, D46, D46.0-D46.2, D46.4-D46.7, D46.9
Other haematology (MPD) ICD10: D45, D47.1, D47.3-D47.5
www.chemodataset.nhs.uk ciu@sph.nhs.uk helpdesk 01865 334 783